

Victor E Reuter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11914730/publications.pdf>

Version: 2024-02-01

236
papers

40,703
citations

3334

91
h-index

2629

194
g-index

243
all docs

243
docs citations

243
times ranked

34127
citing authors

#	ARTICLE	IF	CITATIONS
1	Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology. Archives of Pathology and Laboratory Medicine, 2022, 146, 440-450.	2.5	73
2	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	9.0	4
3	Integrating digital pathology into clinical practice. Modern Pathology, 2022, 35, 152-164.	5.5	42
4	Efficient Visualization of Whole Slide Images in Web-based Viewers for Digital Pathology. Archives of Pathology and Laboratory Medicine, 2022, 146, 1273-1280.	2.5	4
5	Adult Wilms Tumor. American Journal of Surgical Pathology, 2022, Publish Ahead of Print, .	3.7	1
6	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus, 2022, 8, 1278-1288.	3.1	11
7	Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. Journal of Urology, 2022, 208, 309-316.	0.4	7
8	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Modern Pathology, 2022, 35, 825-835.	5.5	14
9	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	3.0	6
10	DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. JCO Precision Oncology, 2022, , .	3.0	1
11	Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. Histopathology, 2022, 81, 246-254.	2.9	6
12	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	1.9	35
13	Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Modern Pathology, 2021, 34, 445-456.	5.5	15
14	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28
15	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
16	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
17	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 2021, 34, 1596-1607.	5.5	17
18	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. Annals of Thoracic Surgery, 2021, 111, 1141-1149.	1.3	4

#	ARTICLE	IF	CITATIONS
19	EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1921-1934.	5.5	28
20	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
21	Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 33-38.	0.6	18
22	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
23	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	7.0	12
24	Integrated digital pathology at scale: A solution for clinical diagnostics and cancer research at a large academic medical center. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1874-1884.	4.4	39
25	Clinical utility of subclassifying positive surgical margins at radical prostatectomy. <i>BJU International</i> , 2021, . .	2.5	2
26	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.4	2
27	Digital Pathology Operations at an NYC Tertiary Cancer Center During the First 4 Months of COVID-19 Pandemic Response. <i>Academic Pathology</i> , 2021, 8, 23742895211010276.	1.1	18
28	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021, 274, e1099-e1107.	4.2	9
29	Practice Patterns in Reporting Tertiary Grades at Radical Prostatectomy: Survey of a Large Group of Experienced Urologic Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 356-360.	2.5	1
30	Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1. <i>Cell Metabolism</i> , 2020, 31, 105-114.e3.	16.2	100
31	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	3.7	31
32	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. <i>Human Pathology</i> , 2020, 103, 1-13.	2.0	10
33	Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC). <i>American Journal of Surgical Pathology</i> , 2020, 44, 901-916.	3.7	34
34	Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. <i>Journal of Pathology</i> , 2020, 250, 464-465.	4.5	8
35	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , 2020, 144, 111-116.	1.0	5
36	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	4.1	22

#	ARTICLE	IF	CITATIONS
37	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	3.0	9
38	Validation of a digital pathology system including remote review during the COVID-19 pandemic. Modern Pathology, 2020, 33, 2115-2127.	5.5	112
39	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 2020, 38, 1332-1337.	1.6	11
40	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516.	3.9	10
41	<i>PTEN</i> Loss with <i>ERG</i> Negative Status is Associated with Lethal Disease after Radical Prostatectomy. Journal of Urology, 2020, 203, 344-350.	0.4	12
42	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.4	58
43	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.4	28
44	(Re) Defining the High-Power Field for Digital Pathology. Journal of Pathology Informatics, 2020, 11, 33.	1.7	16
45	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.4	0
46	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764.	1.9	80
47	Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nature Medicine, 2019, 25, 1301-1309.	30.7	1,320
48	Implementation of Digital Pathology Offers Clinical and Operational Increase in Efficiency and Cost Savings. Archives of Pathology and Laboratory Medicine, 2019, 143, 1545-1555.	2.5	81
49	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer, 2019, 17, 373-379.e4.	1.9	33
50	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2019, 37, 2329-2337.	1.6	17
51	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	7.1	839
52	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019, 75, 453-467.	2.9	3
53	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	5.5	49
54	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	4.5	37

#	ARTICLE	IF	CITATIONS
55	Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. <i>Modern Pathology</i> , 2019, 32, 1329-1343.	5.5	39
56	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 88, 48-59.	2.0	2
57	Whole-Slide imaging equivalency and efficiency study: experience at a large academic center. <i>Modern Pathology</i> , 2019, 32, 916-928.	5.5	134
58	TFEB Expression Profiling in Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1445-1461.	3.7	38
59	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	3.7	59
60	Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3-Tesla. <i>Magnetic Resonance Imaging</i> , 2019, 55, 93-102.	1.8	17
61	Non-Urothelial carcinomas of the bladder. <i>Histopathology</i> , 2019, 74, 97-111.	2.9	29
62	Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. <i>Modern Pathology</i> , 2019, 32, 701-709.	5.5	29
63	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 201-204.	3.1	30
64	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	3.1	40
65	Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 77-83.	0.4	30
66	Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 535-540.	0.4	19
67	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	6.0	31
68	Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features. <i>American Journal of Surgical Pathology</i> , 2018, 42, 767-777.	3.7	33
69	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	6.4	523
70	NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. <i>American Journal of Surgical Pathology</i> , 2018, 42, 636-645.	3.7	97
71	Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?. <i>Journal of Urology</i> , 2018, 199, 1502-1509.	0.4	4
72	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. <i>Human Pathology</i> , 2018, 77, 63-69.	2.0	27

#	ARTICLE	IF	CITATIONS
73	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 961-968.	0.4	7
74	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	7.0	85
75	Urothelial neoplasms in pediatric and young adult patients: A large single-center series. <i>Journal of Pediatric Surgery</i> , 2018, 53, 306-309.	1.6	21
76	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	3.7	34
77	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2018, 36, 3553-3559.	1.6	49
78	Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1562-1570.	3.7	35
79	Granular Cell Tumor of the Bladder: A Report of Six Cases. <i>Urology</i> , 2018, 121, 203.e1-203.e5.	1.0	5
80	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	3.7	22
81	Comedonecrosis Revisited. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1036-1041.	3.7	44
82	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	6.4	324
83	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017, 8, 15165.	12.8	61
84	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
85	RBM10-TFE3 Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 655-662.	3.7	92
86	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	2.0	89
87	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	28.9	1,742
88	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. <i>Modern Pathology</i> , 2017, 30, 1476-1488.	5.5	51
89	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	3.1	43
90	Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer. <i>World Journal of Radiology</i> , 2017, 9, 134.	1.1	1

#	ARTICLE	IF	CITATIONS
91	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
92	TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. <i>American Journal of Surgical Pathology</i> , 2016, 40, 723-737.	3.7	168
93	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2016, 70, 93-105.	1.9	2,211
94	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	1.6	69
95	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	8.8	746
96	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	12.8	140
97	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1457-1472.	3.7	112
98	TFEB-amplified Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1484-1495.	3.7	109
99	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. <i>European Urology</i> , 2016, 70, 106-119.	1.9	1,323
100	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
101	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.4	36
102	An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 29, 104-116.	16.8	531
103	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	27.0	1,040
104	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016, 69, 428-435.	1.9	1,039
105	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
106	Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. <i>European Radiology</i> , 2015, 25, 2840-2850.	4.5	322
107	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2015, 67, 198-201.	1.9	122
108	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. <i>Modern Pathology</i> , 2015, 28, 845-853.	5.5	127

#	ARTICLE	IF	CITATIONS
109	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	2.9	41
110	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 310-315.	0.4	36
111	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	7.0	163
112	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977.	1.9	202
113	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. <i>Modern Pathology</i> , 2015, 28, 1603-1612.	5.5	100
114	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	5.5	106
115	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015, 10, e0142846.	2.5	18
116	Anatomy of the Urinary Bladder Revisited: Implications for Diagnosis and Staging of Bladder Cancer. , 2015, , 173-187.		0
117	Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors. <i>American Journal of Surgical Pathology</i> , 2014, 38, e35-e49.	3.7	110
118	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. <i>American Journal of Surgical Pathology</i> , 2014, 38, 756-767.	3.7	439
119	t(6;11) Renal Cell Carcinoma (RCC). <i>American Journal of Surgical Pathology</i> , 2014, 38, 604-614.	3.7	91
120	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.	7.0	208
121	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.4	15
122	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 914-919.	0.4	39
123	Presence of Somatic Mutations within <i>PIK3CA</i> , <i>AKT</i> , <i>RAS</i> , and <i>FGFR3</i> but not <i>BRAF</i> in Cisplatin-Resistant Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 3712-3720.	7.0	88
124	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.4	49
125	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 192, 702-707.	0.4	61
126	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3133-3140.	1.6	282

#	ARTICLE	IF	CITATIONS
127	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854.	1.9	198
128	ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. <i>European Urology</i> , 2013, 63, 16-35.	1.9	107
129	Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. <i>Journal of Urology</i> , 2013, 190, 407-416.	0.4	264
130	An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1862-1870.	6.3	231
131	Renal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1518-1531.	3.7	154
132	<scp><i>TMPRSS2</i></i></i></i>“ERG</i></i></i>“</i></i></i> rearrangement in dominant anterior prostatic tumours: incidence and correlation with <scp>ERG</scp> immunohistochemistry. <i>Histopathology</i> , 2013, 63, 279-286.	2.9	20
133	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i>: A Report by MSKCC and the KIRC TCGA Research Network. <i>Clinical Cancer Research</i> , 2013, 19, 3259-3267.	7.0	301
134	Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. <i>Modern Pathology</i> , 2012, 25, 1534-1542.	5.5	41
135	Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. <i>Radiology</i> , 2012, 265, 478-487.	7.3	81
136	Molecular genetics of testicular germ cell tumors. <i>American Journal of Cancer Research</i> , 2012, 2, 153-67.	1.4	31
137	Differential Diagnosis of Renal Tumors With Papillary Architecture. <i>Advances in Anatomic Pathology</i> , 2011, 18, 120-131.	4.3	63
138	Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 962-970.	3.7	115
139	Somatic mutation of fibroblast growth factor receptorâ€³ (<i>FGFR3</i>) defines a distinct morphological subtype of highâ€grade urothelial carcinoma. <i>Journal of Pathology</i> , 2011, 224, 270-279.	4.5	73
140	Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippelâ€Lindau gene and hypoxia-inducible factor pathway-related proteins. <i>Modern Pathology</i> , 2011, 24, 1207-1220.	5.5	165
141	Characterization of <i>KRAS</i> Rearrangements in Metastatic Prostate Cancer. <i>Cancer Discovery</i> , 2011, 1, 35-43.	9.4	91
142	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1367-1376.	3.7	111
143	Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1295-1303.	3.7	181
144	Integrative Genomic Profiling of Human Prostate Cancer. <i>Cancer Cell</i> , 2010, 18, 11-22.	16.8	3,151

#	ARTICLE	IF	CITATIONS
145	Differential diagnosis of renal tumours with clear cell histology. <i>Pathology</i> , 2010, 42, 374-383.	0.6	59
146	TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. <i>Modern Pathology</i> , 2010, 23, 1325-1333.	5.5	95
147	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. <i>Modern Pathology</i> , 2010, 23, 1104-1112.	5.5	204
148	An Exploratory Study of Endorectal Magnetic Resonance Imaging and Spectroscopy of the Prostate as Preoperative Predictive Biomarkers of Biochemical Relapse After Radical Prostatectomy. <i>Journal of Urology</i> , 2010, 184, 2320-2327.	0.4	15
149	Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles. <i>Clinical Cancer Research</i> , 2009, 15, 3842-3849.	7.0	34
150	Prostate Tumor Volume Measurement with Combined T2-weighted Imaging and Diffusion-weighted MR: Correlation with Pathologic Tumor Volume. <i>Radiology</i> , 2009, 252, 449-457.	7.3	194
151	Clinical Stage T1c Prostate Cancer: Evaluation with Endorectal MR Imaging and MR Spectroscopic Imaging. <i>Radiology</i> , 2009, 253, 425-434.	7.3	57
152	TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy. <i>Cancer Research</i> , 2009, 69, 1400-1406.	0.9	231
153	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247.	1.6	70
154	Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. <i>Modern Pathology</i> , 2009, 22, 1066-1074.	5.5	85
155	Regarding the Focal Treatment of Prostate Cancer: Inference of the Gleason Grade From Magnetic Resonance Spectroscopic Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 110-114.	0.8	16
156	Correlation of MR Imaging and MR Spectroscopic Imaging Findings with Ki-67, Phospho-Akt, and Androgen Receptor Expression in Prostate Cancer. <i>Radiology</i> , 2009, 250, 803-812.	7.3	29
157	Prognostic Impact of Histological Subtype on Surgically Treated Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2009, 182, 2132-2136.	0.4	110
158	Tumor Size is Associated With Malignant Potential in Renal Cell Carcinoma Cases. <i>Journal of Urology</i> , 2009, 181, 2033-2036.	0.4	251
159	Urachal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 659-668.	3.7	235
160	Estrogen and progesterone-receptor-positive stroma as a non-tumorous proliferation in kidneys: a possible metaplastic response to obstruction. <i>Modern Pathology</i> , 2008, 21, 60-65.	5.5	26
161	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	16.8	303
162	The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by 111Indium-labeled humanized monoclonal antibody 3S193. <i>European Journal of Radiology</i> , 2008, 67, 292-299.	2.6	6

#	ARTICLE	IF	CITATIONS
163	Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage. <i>Cancer Research</i> , 2008, 68, 6054-6058.	0.9	71
164	Prostate Cancer: Identification with Combined Diffusion-weighted MR Imaging and 3D ¹ H MR Spectroscopic Imaging—Correlation with Pathologic Findings ¹ . <i>Radiology</i> , 2008, 246, 480-488.	7.3	200
165	Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 377-382.	3.7	96
166	Detection of Prostate Cancer with MR Spectroscopic Imaging: An Expanded Paradigm Incorporating Polyamines. <i>Radiology</i> , 2007, 245, 499-506.	7.3	88
167	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3967-3972.	7.1	445
168	Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1375-1383.	6.3	248
169	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19458-19463.	7.1	336
170	Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1149-1160.	3.7	381
171	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. <i>Lancet Oncology</i> , The, 2007, 8, 304-310.	10.7	370
172	Urachal Carcinoma: Contemporary Surgical Outcomes. <i>Journal of Urology</i> , 2007, 178, 74-78.	0.4	137
173	The pathology of bladder cancer. <i>Urology</i> , 2006, 67, 11-17.	1.0	73
174	Angiomyolipoma With Epithelial Cysts (AMLEC). <i>American Journal of Surgical Pathology</i> , 2006, 30, 593-599.	3.7	129
175	The Pathology of Renal Epithelial Neoplasms. <i>Seminars in Oncology</i> , 2006, 33, 534-543.	2.2	121
176	Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors. <i>Cancer Research</i> , 2006, 66, 820-827.	0.9	275
177	Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 5442-5447.	7.0	81
178	Translocation Carcinomas of the Kidney After Chemotherapy in Childhood. <i>Journal of Clinical Oncology</i> , 2006, 24, 1529-1534.	1.6	227
179	Renal Carcinomas With the t(6;11)(p21;q12). <i>American Journal of Surgical Pathology</i> , 2005, 29, 230-240.	3.7	279
180	Gene expression-based classification of nonseminomatous male germ cell tumors. <i>Oncogene</i> , 2005, 24, 5101-5107.	5.9	57

#	ARTICLE	IF	CITATIONS
181	Origins and molecular biology of testicular germ cell tumors. <i>Modern Pathology</i> , 2005, 18, S51-S60.	5.5	149
182	Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. <i>Cancer</i> , 2005, 104, 290-298.	4.1	147
183	Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy. <i>Radiology</i> , 2005, 234, 804-814.	7.3	386
184	Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 71-77.	1.5	244
185	Feasibility of Radical Prostatectomy After Neoadjuvant Chemohormonal Therapy for Patients With High Risk or Locally Advanced Prostate Cancer: Results of a Phase I/II Study. <i>Journal of Urology</i> , 2004, 171, 709-713.	0.4	83
186	Nested Variant of Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Study of 12 Cases. <i>Modern Pathology</i> , 2003, 16, 1289-1298.	5.5	93
187	Long-term follow-up of bilateral sporadic renal tumors. <i>Urology</i> , 2003, 61, 921-925.	1.0	51
188	Transition Zone Prostate Cancer: Metabolic Characteristics at ¹ H MR Spectroscopic Imaging—Initial Results. <i>Radiology</i> , 2003, 229, 241-247.	7.3	168
189	Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2003, 27, 750-761.	3.7	562
190	Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. <i>Cancer Immunity</i> , 2003, 3, 19.	3.2	36
191	PRCC-TFE3 Renal Carcinomas. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1553-1566.	3.7	306
192	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2002, 167, 1295-1298.	0.4	544
193	Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. <i>Urology</i> , 2002, 60, 1003-1009.	1.0	128
194	The pre and post chemotherapy pathologic spectrum of germ cell tumors. <i>Chest Surgery Clinics of North America</i> , 2002, 12, 673-694.	0.7	11
195	Bladder Neck Involvement in Pathological Stage pT4 Radical Prostatectomy Specimens is Not An Independent Prognostic Factor. <i>Journal of Urology</i> , 2002, 168, 2011-2015.	0.4	62
196	MECHANISMS OF PROSTATIC STROMAL INVASION IN PATIENTS WITH BLADDER CANCER: CLINICAL SIGNIFICANCE. <i>Journal of Urology</i> , 2001, 165, 1117-1120.	0.4	63
197	Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma. <i>American Journal of Pathology</i> , 2001, 159, 179-192.	3.8	601
198	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. <i>Journal of Urology</i> , 2001, 166, 2295-2296.	0.4	232

#	ARTICLE	IF	CITATIONS
199	Sex Cordâ€“Stromal Tumors of the Testis With Entrapped Germ Cells. American Journal of Surgical Pathology, 2000, 24, 535-542.	3.7	65
200	Primary Renal Synovial Sarcoma. American Journal of Surgical Pathology, 2000, 24, 1087-1096.	3.7	235
201	Warty (Condylomatous) Squamous Cell Carcinoma of the Penis. American Journal of Surgical Pathology, 2000, 24, 505-512.	3.7	162
202	Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. , 2000, 88, 407-415.		27
203	Immunophenotype of High-Grade Prostatic Adenocarcinoma and Urothelial Carcinoma. Modern Pathology, 2000, 13, 1186-1191.	5.5	141
204	Intrarenal Schwannoma: A Report of Four Cases Including Three Cellular Variants. Modern Pathology, 2000, 13, 851-856.	5.5	43
205	SURGICAL MANAGEMENT OF RENAL TUMORS 4 CM. OR LESS IN A CONTEMPORARY COHORT. Journal of Urology, 2000, 163, 730-736.	0.4	581
206	Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer, 2000, 88, 407-415.	4.1	1
207	Progression of T1 bladder tumors. , 1999, 86, 908-909.		10
208	Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene, 1998, 16, 2345-2349.	5.9	148
209	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. Oncogene, 1998, 17, 761-767.	5.9	31
210	Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine, 1998, 4, 50-57.	30.7	249
211	EVALUATION OF NEW RESECTOSCOPE LOOP FOR TRANSURETHRAL RESECTION OF BLADDER TUMORS. Journal of Urology, 1998, 159, 2067-2068.	0.4	16
212	Basaloid Squamous Cell Carcinoma: A Distinctive Human Papilloma Virus-Related Penile Neoplasm. American Journal of Surgical Pathology, 1998, 22, 755-761.	3.7	156
213	Diagnostic Significance of Mitochondria in Four Types of Renal Epithelial Neoplasms: An Ultrastructural Study of 60 Tumors. Ultrastructural Pathology, 1997, 21, 409-417.	0.9	78
214	Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 1997, 49, 16-22.	1.0	126
215	Glutathione S-transferase PI (GST-pi) Class Expression by Immunohistochemistry in Benign and Malignant Prostate Tissue. Journal of Urology, 1997, 157, 673-676.	0.4	86
216	The Heidelberg classification of renal cell tumours. Journal of Pathology, 1997, 183, 131-133.	4.5	1,142

#	ARTICLE	IF	CITATIONS
217	Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. , 1997, 33, 225-232.		78
218	Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. International Journal of Cancer, 1997, 73, 42-49.	5.1	254
219	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. , 1997, 73, 50-56.		212
220	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. International Journal of Cancer, 1997, 73, 50-56.	5.1	2
221	Workgroup 3: Current prognostic factors and their relevance to staging. , 1996, 78, 369-371.		11
222	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. , 1996, 69, 110-113.		34
223	Intraoperative touch-imprint cytology of germ cell neoplasms. , 1996, 14, 393-394.		8
224	Comparative genomic hybridization for genetic analysis of renal oncocytomas. Genes Chromosomes and Cancer, 1996, 17, 199-204.	2.8	65
225	Comparative genomic hybridization for genetic analysis of renal oncocytomas. Genes Chromosomes and Cancer, 1996, 17, 199-204.	2.8	3
226	p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. International Journal of Cancer, 1994, 56, 347-353.	5.1	220
227	Neuroendocrine Differentiation in Metastatic Prostatic Adenocarcinoma. Journal of Urology, 1994, 151, 914-919.	0.4	95
228	Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer, 1993, 71, 3952-3965.	4.1	197
229	Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes and Cancer, 1993, 8, 230-236.	2.8	141
230	Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer. Diagnostic Molecular Pathology, 1993, 2, 4-13-13.	2.1	40
231	Expression of blood group antigens in bladder cancer: Current concepts. Journal of Surgical Oncology, 1992, 8, 308-315.	1.4	14
232	Blood group antigens in normal and neoplastic urothelium. Journal of Cellular Biochemistry, 1992, 50, 50-55.	2.6	16
233	Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1992, 5, 21-29.	2.8	46
234	Abnormalities of 2q: A common genetic link between rhabdomyosarcoma and hepatoblastoma?. Genes Chromosomes and Cancer, 1991, 3, 122-127.	2.8	62

#	ARTICLE	IF	CITATIONS
235	Leukemic differentiation of a mediastinal germ cell tumor. <i>Genes Chromosomes and Cancer</i> , 1989, 1, 83-87.	2.8	109
236	Flow Cytometry and Cytology as Response Indicators to M-VAC (Methotrexate, Vinblastine,) Tj ETQq0 0 0 rgBT /Overlock 10 If 50 702 T	0.4	21